More than 30 European universities and companies, led by GlaxoSmithKline, are joining forces in a six-year programme funded by the Innovative Medicines Initiative (IMI) for the sum of EUR 85 millions with the aim of developing new antibiotics against Gram-negative pathogens. The programme is called ENABLE (European Gram-Negative Antibacterial Engine). The University of Liège, with its Centre for Protein Engineering (CIP), is the only Belgian university to collaborate closely in this ambitious programme to discover new antibiotics, which is the largest one in Europe.
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...